[go: up one dir, main page]

UY37113A - Compuestos, composiciones y métodos para la estratificación de pacientes de cáncer y su tratamiento - Google Patents

Compuestos, composiciones y métodos para la estratificación de pacientes de cáncer y su tratamiento

Info

Publication number
UY37113A
UY37113A UY0001037113A UY37113A UY37113A UY 37113 A UY37113 A UY 37113A UY 0001037113 A UY0001037113 A UY 0001037113A UY 37113 A UY37113 A UY 37113A UY 37113 A UY37113 A UY 37113A
Authority
UY
Uruguay
Prior art keywords
compounds
methods
treatment
stratification
compositions
Prior art date
Application number
UY0001037113A
Other languages
English (en)
Inventor
Martin Lange Dr
Antje Margret Wengner Dra
Ulrike Sack Dra
Heidi Greulich
Matthew Meyerson
De Waal Luc
Monica Schenone
Alex Burgin
A Lewis Timothy
Xiaoyun Wu
Philip Lienau Dr
Knut Eis Dr
Original Assignee
Dana Farber Cancer Inst Inc
Broad Inst Inc
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc, Broad Inst Inc, Bayer Pharma AG filed Critical Dana Farber Cancer Inst Inc
Publication of UY37113A publication Critical patent/UY37113A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Compuestos mejorados, especialmente métodos para identificar pacientes que padecen de cáncer usando biomarcadores (por ejemplo, PDE3A, SLFN12 y/o CREB3L1) que están correlacionados con la sensibilidad al fármaco, y para someter la población de pacientes estratificados al tratamiento correspondiente con un agente de la invención (por ejemplo, los compuestos 1-6 descriptos en la presente).
UY0001037113A 2016-02-05 2017-02-03 Compuestos, composiciones y métodos para la estratificación de pacientes de cáncer y su tratamiento UY37113A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662291935P 2016-02-05 2016-02-05

Publications (1)

Publication Number Publication Date
UY37113A true UY37113A (es) 2017-08-31

Family

ID=58009797

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037113A UY37113A (es) 2016-02-05 2017-02-03 Compuestos, composiciones y métodos para la estratificación de pacientes de cáncer y su tratamiento

Country Status (9)

Country Link
US (3) US10966986B2 (es)
EP (1) EP3411037B1 (es)
JP (1) JP7148403B2 (es)
CN (2) CN114601837A (es)
AR (1) AR107529A1 (es)
CA (2) CA3013402C (es)
TW (1) TW201733591A (es)
UY (1) UY37113A (es)
WO (1) WO2017134231A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11207320B2 (en) 2015-08-13 2021-12-28 The Broad Institute, Inc. Compositions and methods for cancer expressing PDE3A or SLFN12
EP3411037B1 (en) * 2016-02-05 2021-10-20 Bayer Pharma Aktiengesellschaft Compounds, compositions and methods for cancer patient stratification and cancer treatment
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
WO2018141835A1 (en) * 2017-02-03 2018-08-09 The Broad Institute, Inc. Compounds, compositions and methods for cancer treatment
EP3661917B1 (en) 2017-08-04 2022-05-11 Bayer Aktiengesellschaft 6-((3-trifluoromethyl)phenyl)-4,5-dihydropyridazin-3(2h)-one derivatives as pde3a and pde3b inhibitors for treating cancer
JOP20200024A1 (ar) 2017-08-04 2020-02-02 Bayer Ag مركبات ثنائي هيدروكساديازينون
JP7104588B2 (ja) * 2017-09-01 2022-07-21 大塚製薬株式会社 ５－メチル－６－フェニル－４，５－ジヒドロ－２ｈ－ピリダジン－３－オン誘導体を含有する悪性腫瘍治療剤
WO2019203168A1 (ja) * 2018-04-16 2019-10-24 学校法人順天堂 骨髄増殖性腫瘍の診断
WO2020157236A1 (en) * 2019-02-01 2020-08-06 Bayer Aktiengesellschaft Pyridyl substituted dihydrooxadiazinones
CA3128293A1 (en) 2019-02-01 2020-08-06 Bayer Aktiengesellschaft 1,2,4-triazin-3(2h)-one compounds for the treatment of hyperproliferative diseases
WO2020157199A1 (en) * 2019-02-01 2020-08-06 Bayer Aktiengesellschaft Annulated dihydropyridazinone compounds as anti-cancer compounds
CN110894529A (zh) * 2019-12-16 2020-03-20 新乡医学院 一种与结直肠癌早期诊断相关的环状rna标志物、检测引物、试剂盒及其应用
CN114578053B (zh) * 2020-12-01 2025-11-18 南通思特康生物科技有限公司 一种检测微卫星不稳定的分子标志物及应用
CN117279644A (zh) * 2021-03-03 2023-12-22 拜耳股份有限公司 用于治疗肉瘤的取代的3,6-二氢-2h-1,3,4-噁二嗪-2-酮
CN113176408B (zh) * 2021-06-02 2022-10-11 四川大学华西医院 一种甲状腺癌预后情况判断的方法
WO2023105119A1 (en) * 2021-12-07 2023-06-15 Sartar Therapeutics Oy Synergistic compositions for use in the treatment of cancer
AU2024268099A1 (en) * 2023-05-08 2025-09-18 Otsuka Pharmaceutical Co., Ltd. Inhibitor of megakaryocyte differentiation and maturation
CN116893250A (zh) * 2023-05-31 2023-10-17 杭州娃哈哈科技有限公司 一种快速评估胶态级微晶纤维素在中性乳饮料中应用性能的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8426804D0 (en) 1984-10-23 1984-11-28 Ciba Geigy Ag Pyridazinones preparations
US5856480A (en) * 1994-11-11 1999-01-05 Nippon Soda Co., Ltd. Optically active compound
CA2624086A1 (en) * 2005-09-28 2007-04-05 H. Lee Moffitt Cancer Center Individualized cancer treatments
JP5984324B2 (ja) * 2005-12-01 2016-09-06 メディカル プログノシス インスティテュート エー／エス 治療反応のバイオマーカーを同定するための方法および装置、ならびに治療効果を推定するためのその使用
EP2675440B1 (en) 2011-02-14 2020-03-25 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
US9890127B2 (en) * 2013-03-11 2018-02-13 The Broad Institute, Inc. Compounds and compositions for the treatment of cancer
WO2015077565A1 (en) 2013-11-22 2015-05-28 Board Of Regents, The University Of Texas System Treating cancers with drugs targeting creb3l1
US11207320B2 (en) 2015-08-13 2021-12-28 The Broad Institute, Inc. Compositions and methods for cancer expressing PDE3A or SLFN12
EP3411037B1 (en) 2016-02-05 2021-10-20 Bayer Pharma Aktiengesellschaft Compounds, compositions and methods for cancer patient stratification and cancer treatment
WO2018141835A1 (en) * 2017-02-03 2018-08-09 The Broad Institute, Inc. Compounds, compositions and methods for cancer treatment

Also Published As

Publication number Publication date
WO2017134231A1 (en) 2017-08-10
JP2019508404A (ja) 2019-03-28
CA3234176A1 (en) 2017-08-10
US10966986B2 (en) 2021-04-06
AR107529A1 (es) 2018-05-09
CA3013402A1 (en) 2017-08-10
TW201733591A (zh) 2017-10-01
US20240366620A1 (en) 2024-11-07
EP3411037A1 (en) 2018-12-12
US20210236504A1 (en) 2021-08-05
CN108883112A (zh) 2018-11-23
US20190365770A1 (en) 2019-12-05
EP3411037B1 (en) 2021-10-20
CN108883112B (zh) 2022-07-26
JP7148403B2 (ja) 2022-10-05
CA3013402C (en) 2024-05-28
CN114601837A (zh) 2022-06-10
US12053476B2 (en) 2024-08-06

Similar Documents

Publication Publication Date Title
UY37113A (es) Compuestos, composiciones y métodos para la estratificación de pacientes de cáncer y su tratamiento
CO2019013010A2 (es) Inhibidores de kras g12c y métodos para su uso
MX384884B (es) Inhibidores de ret.
CO2018001149A2 (es) Anticuerpos monoclonales contra bcma
MX2016002137A (es) Ciertas entidades quimicas, composiciones y metodos.
CL2017001459A1 (es) Biarilo compuestos útiles para el tratamiento de enfermedades humanas en oncología, neurología e inmunología
MX2019003735A (es) Formulaciones diluibles de cannabinoides y procesos para su preparacion.
MX2015012437A (es) Esteroides neuroactivos, composiciones, y usos de los mismos.
CL2019001330A1 (es) Inhibidores de la tirosina quinasa de bruton.
CL2021002503A1 (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos. (divisional de solicitud 201902251)
CY1119042T1 (el) Υποκατεστημενες ξανθινες και μεθοδοι χρησης αυτων
MX378969B (es) Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres.
MX388405B (es) Un anticuerpo anti-pd-l1 para usarse en el tratamiento de cáncer en sujetos que tienen nivel medio o bajo de metilación en la región promotora pd-l1.
CL2018000596A1 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
MX2016007111A (es) Inhibidores de tirosina quinasa de bruton.
CU20160185A7 (es) Compuestos de heteroarilo para la inhibición de cinasa
CL2011000691A1 (es) Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
MX375378B (es) Formulaciones de anticuerpos anti-pdl1.
UY35500A (es) Indazoles sustituidos con heteroarilo
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
CY1125150T1 (el) Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου
CR20160270A (es) ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
CO2018002568A2 (es) Acetamida tienotriazolodiazepinas y usos de las mismas
BR112017006468A2 (pt) anticorpo biespecífico, composição farmacêutica, kit, uso de uma combinação de um anticorpo biespecífico e método de tratamento de câncer
MX2018016057A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20230601